Advanced Filters
noise

Torino, Piemonte, Italy Clinical Trials

A listing of Torino, Piemonte, Italy clinical trials actively recruiting patients volunteers.

Found 193 clinical trials
T Tommaso D'Angelo, M.D.

CCT for Comprehensive Risk Stratification Following STEMI

The CT-STEMI study aims to evaluate a comprehensive cardiac computed tomography (CCT) protocol for assessing the risk of heart failure (HF), life-threatening arrhythmias (LTA), and atherothrombotic events following ST-elevation myocardial infarction (STEMI). This multicenter, prospective study has three main objectives: Comparing the diagnostic accuracy of the comprehensive CCT protocol with …

18 years of age All Phase N/A
C Carmine Selleri, MD

Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

This is an open-label, multicenter, randomized phase III trial. The study plans to randomize patients with a 1 to 1 ratio to Arm A (Standard arm) or Arm B (Experimental arm). All patients of both arms will receive a prephase with oral prednisone before 6 cycles Q21 of immunochemotherapy with …

65 years of age All Phase 3
G Giovanni Lodi

Oral Potentially Malignant Disorders: Comparison Between Surgical Treatment and Wait and See Approach

This research protocol is comparing the effectiveness of surgical excision to the "wait and see" approach for the management of oral leukoplakia and erythroleukoplakia in prevention of oral squamous cell carcinoma onset.

18 years of age All Phase N/A
F Fabio Ciceri, MD

Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT)

Open-label, randomized multicenter phase III non-inferiority study

18 - 70 years of age All Phase 3

Safety and Efficacy of Adaptive Deep Brain Stimulation

The aim of this study is to assess the safety and the potential efficacy of personalized Local Field Potential (LFP)-based adaptive Deep Brain Stimulation (aDBS), using the implantable pulse generator (IPG) of the "AlphaDBS" System, in Parkinson's Disease patients, chronically implanted in subthalamic nucleus (STN) for DBS, at the time …

years of age All Phase N/A
M Mario Aimetti, Prof.

Multi-omics Analysis of Oral-gut Microbial Profiles

Periodontitis is a chronic inflammatory disease of the tooth supporting structures induced by a dysbiosis in the oral and subgingival microenvironment of susceptible patients. The long-term swallowing of high doses of periodontal pathogenic microorganisms could induce a dysbiosis of the intestinal microbiota, favouring the establishment of an 'inflamed' microbiome in …

18 years of age All Phase N/A
J Jacopo Lanzetti, Dr.

Efficacy of a Xanthan-based Chlorhexidine Gel in the Treatment of Peri-implant Mucositis

The peri-implant mucositis is an inflammatory and reversible lesion that surrounds the peri-implant mucosa without loss of supporting bone, clinically characterized by bleeding on gentle probing. It has been estimated that it affects approximately 21% to 88% of individuals and 9% to 51% of implant sites, with prevalences of 47% …

18 - 90 years of age All Phase N/A
P Paolo Bironzo

Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC)

A prospective multicenter, single-arm phase II study enrolling treatment-naïve patients with metastatic pulmonary large-cell neuroendocrine carcinoma (LCNEC)

18 years of age All Phase 2
I Irene Carrasco, MD

Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients

Phase I-II trial that combines trabectedin plus radiotherapy for tumor reduction response measure in four cohorts of patients: Cohort A: Patients with diagnosis of non-operable or unresectable or not oncologically recommended metastasectomy of limited to lung metastases soft tissue sarcoma. Cohort B: Patients with locally advanced resectable Myxoid Liposarcoma. Cohort …

18 years of age All Phase 1/2
I Isacco Desideri, MD, radiation oncologist

Regorafenib for Recurrent Grade 2 and 3 Meningioma (MIRAGE Trial)

The focus of this study will be to investigate whether Regorafenib demonstrates antitumor activity against recurrent grade II or III meningiomas. Small trials and case series suggest clinical relevant activity of several VEGF inhibitors such as sunitinib, bevacizumab and valatinib reporting a 6m-PFS rate of 42-64%. Indeed, VEGF and VEGF …

18 years of age All Phase 2

Simplify language using AI